A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of
Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric
or Gastroesophageal Junction Cancer patients, to ensure adequate treatment dosage for further
study. Meanwhile, the study also evaluate Pharmacokinetics of Gentuximab Injection at
different dosage in combination with Paclitaxel.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GeneScience Pharmaceuticals Co., Ltd.
Collaborators:
First Hospital of Jilin University Fujian Tumor Hospital Shanghai East Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Sir Run Run Shaw Hospital Sixth Affiliated Hospital, Sun Yat-sen University The Affiliated Tumor Hospital of Harbin Medical University The First Affiliated Hospital of Zhengzhou University The First Affiliated Hospital with Nanjing Medical University The First Affiliated Hospital, Zhejiang University School of Medicine The First Hospital of Jilin University The Sixth Hospital of Sun Yat-sen University Tongji Hospital Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Union Hospital of Tongji Medical College, Huazhong University of Science and Technology